We have shown that the SUR1/TRPM4 channel is upregulated in rodent models of ischemic stroke, and that we can significantly attenuate injury with administration of glibenclamide at non-hypoglycemic doses. Importantly, an archival study found that patients with type-2 diabetes who had a sulfonylurea on-board at the time of stroke had substantially improved outcomes over patients that were not taking a sulfonylurea.
We have recently completed the first of several studies aimed at characterizing the window of efficacy for glibenclamide administration.
Supported by the discoveries from this laboratory, the use of glibenclamide for the treatment of ischemic stroke is currently in a Phase II clinical trial (GAMES-PILOT).
- Glibenclamide-10-h Treatment Window in a Clinically Relevant Model of Stroke.
- Glibenclamide is superior to decompressive craniectomy in a rat model of malignant stroke.
- Protective effect of delayed treatment with low-dose glibenclamide in three models of ischemic stroke.
- Sulfonylureas improve outcome in patients with type 2 diabetes and acute ischemic stroke.
- Non-selective cation channels, transient receptor potential channels and ischemic stroke.
- Newly expressed SUR1-regulated NC(Ca-ATP) channel mediates cerebral edema after ischemic stroke.